Corporate presentation

October 2024



Disclaimer

This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information and for the purpose of providing background information on the Company, its business and the industry in which it operates or any particular aspect thereof. For the purposes of this notice, "presentation" means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during any related presentation meeting.

This presentation has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries, or any of any such person's directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this presentation is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company or any of its subsidiaries, or any of any additional information that may arise in connection with it. To the extent available, the data contained in this presentation has come from official or third-party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained in this presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. Further, certain of the data has been provided to the Company by contract research organizations that the Company retains to conduct clinical trials, or by other third parties contracted by the Company. While the Company believes that such internal research and estimates and such other data are reasonable and reliable, they, and, where applicable, their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness a

Forward-Looking Statements

This presentation contains "forward-looking" statements that involve substantial risks and uncertainties. All statements other than statements of historical fact contained in this presentation are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements relate to future events, including, but not limited to, statements regarding future clinical development, efficacy, safety and therapeutic potential of clinical product candidates, including expectations as to reporting of data, conduct and timing and potential future clinical activity and milestones and expectations regarding the initiation, design and reporting of data from clinical trials. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forwardlooking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct its clinical trials and provide funding for its clinical trials; the Company's dependence on enrollment of patients in its clinical trials; and the Company's dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on March 27, 2024, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the SEC. You should not place undue reliance on any forwardlooking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law. This presentation also contains estimates, projections and other information concerning the Company's business and the markets for the Company's product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events, or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, the Company obtained this industry, business, market and other data from reports, research surveys, clinical trials studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources.



Unlocking the potential of novel targets for rare diseases

Our mission is to improve the lives of people living with rare diseases





Strategic principles guide our journey

- Acquire and develop programs in rare diseases with high prevalence – partner of choice for in-licensing
- Focus on our core competencies and experience in rare diseases
- Develop pipeline of rare disease programs which have already received significant investment and retain global or regional rights where possible (initially in Europe)
- Partner our programs where it makes strategic sense and target monetization of royalty streams for non-core programs





A late-stage rare disease company with a capital efficient model

Achievements and fundamentals

Two rare disease programs in-licensed and progressed to pivotal stage:

- **Setrusumab** for Osteogenesis Imperfecta (OI) in Phase 3 under a partnership with rare disease leader Ultragenyx
- **Alvelestat** for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) successfully completed Phase 2, with Phase 3 endpoints agreed in principle with FDA and EMA

Financial discipline delivers cash runway into 2027

- \$87.5 million of cash and cash equivalents as of June 30, 2024
- Active cost management runway through key inflection points
- Leverage investigator-led studies to expand data sets



A late-stage company with validating partnerships

Corporate development

Management team with a proven track record in corporate development

- Setrusumab acquired from Novartis
- Alvelestat in-licensed from AstraZeneca
- Setrusumab partnered with Ultragenyx whilst retaining European rights
- Navicixizumab global rights licensed to Feng Biosciences and leflutrozole licensed to ReproNovo

Upside potential from etigilimab (an anti-TIGIT antibody) and acumapimod (p38 MAP kinase inhibitor)










Late-stage clinical pipeline with core rare disease programs







"It's always a pleasure to come and speak with people who are actually making a difference on the ground and making a difference for people like myself and for others in the community. Because it is what you do that helps us to live the lives that we want and that we deserve."

Thines Ganeshamoorthy, Trustee at the Brittle Bone Society, speaking at an event to mark Rare Disease Day 2023 at Mereo BioPharma.





Setrusumab (UGX143)

Osteogenesis Imperfecta: a rare genetic bone condition with no FDA or EMA approved therapy



A rare genetic bone condition with a high unmet need

Osteogenesis Imperfecta

- 80-90% linked to a mutation in Type I collagen^{1,2} (Type I, III and IV)
- Frequent bone fractures, skeletal deformities, pain, respiratory and gastric problems
- No FDA / EMA approved therapy. Current standard of care (bisphosphonates) has not been shown to reduce fractures
- Early diagnosis in utero or shortly after birth with symptoms often already present


Market Opportunity

- Affects approximately 60,000 individuals³ (pediatrics and adults) in the US and Europe
- Well-established Community groups (OIFE + national members and OIF)* are a key source of support and valued resource
- OI is a progressive condition, without clear care pathways, especially for adult patients
- Potential market opportunity of >\$1Bn⁴




Setrusumab – Mechanism of Action

Mereo BioPharma



Phase 2b ASTEROID study in adults with OI Types I, III and IV




Statistically significant dose-dependent increases in areal BMD by DXA following 12 months of setrusumab therapy

*p<0.05, **p<0.01, ***p<0.001 vs baseline based on an ANCOVA model with baseline values, treatment group and OI type as covariates. ANCOVA, analysis of covariance; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; OI, osteogenesis imperfecta; SEM, standard error of the mean. At the 20 mg/kg dose - increase in failure load (p=0.037) and stiffness at the radius (p= 0.022) as measured by finite element analysis (FEA). Increase in trabecular bone score (TBS) – 3D bone architecture, helps predict fracture (p<0.001 at 8mg/kg and 20mg/kg).




Orbit Phase 2 – BMD and Z-score mean increase through month 12¹ Improvements consistent across all OI Types studied



Change in lumbar spine BMD from baseline at 12 months = 22% (p<0.0001, n=19) (14% at 6 months) Change in baseline lumbar spine BMD Z-score at 12 months = +1.25 (p<0.0001, n=18) (+0.85 at 6 months)

Mereo BioPharma


Orbit Phase 2 – increase in BMD observed in all age groups,^{1,2} Greatest increase in patients 5-12 years of age






 Data as of June 2024; 2. Lewiecki EM *et al.* Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta: Phase 2 Data from the Phase 2/3 Orbit Study. Presented at the American Society for Bone and Mineral Research; October 13–16, 2023; Vancouver, BC, Canada. Abstract/Poster LB SAT-650 14
 Setrusumab for the Treatment of Osteogenesis Imperfecta: 12-Month Results from the Phase 2b Asteroid Study, Journal of Bone and Mineral research, July 2024

Treatment with setrusumab (mean duration of 16 months) resulted in a 67% reduction in annualized fracture rate (AFR) compared to pre-treatment AFR



1: Data as of June 2024; updated clinical fractures includes a mean follow-up of 16 months 2: Pre-Treatment period includes fractures in the two years before screening based on medical record review and patient report, and fractures between screening and first dose



Mereo BioPharma

Safety evaluation at 14 months shows setrusumab is well tolerated

No treatment-related SAEs No unexpected adverse events or safety concerns No subject discontinued treatment for any adverse event No drug-related hypersensitivity reactions

Most common adverse events (AEs) reported at 6 months*1

Adverse Event at 6 months	Phase 2 Patients (N=24)
Infusion-related events (low grade)	7 (29%)
Headache	3 (13%)
Abdominal discomfort	1 (4%)
Infusion site pain	1 (4%)
Bone pain	1 (4%)
Upper respiratory tract infection	1 (4%)

*All related adverse events were mild to moderate in severity



1. Lewiecki EM et al. Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta: Phase 2 Data from the Phase 2/3 Orbit Study. Presented at the American Society for Bone and Mineral Research; October 13–16, 2023; Vancouver, BC, Canada. Abstract/Poster LB SAT-650

Orbit study – Phase 3* is fully enrolled

To evaluate the efficacy and safety of setrusumab vs. placebo in children and young adults with OI			
Enrolled 158 subjects ages 5 to 25 years with OI Types I, III, or IV and a confirmed <i>COL1A1</i> or <i>COL1A2</i> mutation. Enrolled in 12 countries including USA and Europe (50 sites).	Patients with at least 1 fracture in prior 12 months or 2 fractures in prior 24 months, or 1 fracture of tibia, femur or humerus. Stratified by number of fractures in the prior 2 years (\leq 3 vs >3) and age group.		
Subjects randomized 2:1 to receive 20 mg/kg of setrusumab administered by monthly infusion or placebo administered IV QM. Study is double blinded.	Primary efficacy endpoint of annualized clinical fracture rate (excludes fingers, toes, face and skull).		



Cosmic study – Phase 3* is fully enrolled

To evaluate the efficacy and safety of setrusumab vs. bisphosphonates in young children with OI			
Enrolled 69 subjects ages 2 to < 7 years with OI Types I, III, or IV and a confirmed <i>COL1A1</i> or <i>COL1A2</i> mutation. Enrolled at sites including in the USA and Europe.	Patients with at least 1 fracture in prior 12 months or 2 fractures in prior 24 months or 1 fracture of tibia, femur or humerus. Stratified by number of fractures in the prior 2 years (\leq 3 vs >3) and age group.		
Subjects randomized 1:1 to receive 20 mg/kg of setrusumab administered by monthly infusion or existing bisphosphonate by infusion per investigator discretion. Study is open label.	Primary efficacy endpoint of annualized clinical fracture rate (including morphometric fractures).		



The Ultragenyx partnership, a highly effective collaboration


Key terms

- Signed in December 2020
- Ultragenyx leads and funds the global development plan, including CMC
- Mereo retains European rights (including UK) and Ultragenyx has the USA and Rest of the World rights
- Mereo received \$50M upfront with potential additional \$245M in regulatory and commercial milestones (\$9M received on first patient dosed in Orbit Phase 3 study – July 2023)
- Ultragenyx pays Mereo tiered double digit % royalties on net sales in Ultragenyx territories
- Mereo pays Ultragenyx fixed double digit % royalty on net sales in Mereo territories



Ultragenyx partnership – cash flows

Mereo BioPharma



Critical steps toward commercialization

Navigating the EU regulatory and access pathways to unlock value across the region

Sequential process to de-risk the program and build the data sets that HTA committees and payors will require.

Regulatory/
Payor
engagementEngaged early (since 2019) and regularly with stakeholders to understand needs and
expectations, including: Prime designation, EUnetHTA and MOCA Mechanism of Coordinated
Access to Orphan Medicinal Products. Initial 9 countries represented at EUnetHA.Real World
EvidenceSATURN (Systematic Accumulation of Treatment practices and Utilization, Real world evidence,
and Natural history data for OI). Collaborating with existing data sets and OIFE and OIF.
Will provide coordinated data set across multiple treatment centers for OI across European

countries, to support pricing and reimbursement decisions and scientific publications.

Understanding patients

IMPACT, the largest ever burden of disease survey on the impact of OI on patients, physicians and caregivers, data being published (<u>www.impactsurveyoi.com</u>). 5,000 pediatric and 5,000 adult patients who we believe could be eligible for setrusumab treatment already identified in the key 5 European markets. Scientific publications.

Market opportunity Intensive engagement with highly networked OI specialized treating physicians indicates high level of interest in safe and effective on-label treatment. Potential relevant rare bone analog X-linked hypophosphatemia (XLH), Crysvita launched 2018/2019 in US and EU, 2023 sales \$747M in North America, \$256M in EMEA. 1H 2024 sales of \$388M in North America and \$169M in EMEA (increase of 43% versus 1H 2023).¹





Alvelestat (MPH966)

Alpha-1 Antitrypsin Deficiency-associated Lung Disease: a rare progressive lung disease with high unmet need Alpha 1 Support Group UK Information Day September 2023

AATD-LD: a rare progressive lung disease with high unmet need

Lack of AAT results in risk of progressive lung damage and early onset emphysema

Disease overview

- Presents age 20 to 50, shortness of breath, cough, reduced exercise tolerance
- Severe deficiency patient population estimates: ~50,000 in North America and ~60,000 in Europe and the UK, of which 60-80% develop lung disease¹
- Increasing diagnosis rate

Current treatments create high unmet need

- Currently COPD treated and lifestyle changes
- Intravenous plasma-derived augmentation therapy:
 - Clinical efficacy not uniformly recognized
 - \circ IV administration burden
 - Optimal dose uncertain
 - Not uniform access across US and EU and early-stage patients

Significant market opportunity

- US AAT augmentation revenues reached \$1.4bn in 2022⁴
 - US patients (weekly I.V.) \$100-150k/year⁴
 - AATD products forecast to reach \$3.2bn by 2031⁵
- Europe AAT augmentation not widely reimbursed as lack of clinical outcomes data
- Potential first oral therapy



1. Blanco I et al. 2017. alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update. *Int J COPD*: 12 561-569 2. Evercore estimate

3. Based on Cantor Fitzgerald estimates of Net Peak Sales in the US and EU5

4. Cantor Fitzgerald January 2024 Deep Dive: Alpha-1 Antitrypsin Deficiency and Its Destruction of the Lungs and Liver 5. Global data

Alvelestat – 16 clinical trials in ~2,000 subjects

• Phase 1 (6 studies)

- Safety, PK and pharmacodynamics support safety and dose-decisions
- Phase 2 (9 completed, 1 ongoing), efficacy from respiratory disorders of Neutrophil Elastase/Anti-Elastase imbalance:
 - COPD (2 studies, n~1,500): In one study (n=615) a
 >100ml increase in FEV₁ observed in bronchitic subset (n~200, p< 0.01)¹
 - Bronchiectasis (n=38): >100ml increase in FEV₁ (p= 0.006); numerical improvement St. George's Respiratory Questionnaire (SGRQ)²
 - Cystic Fibrosis (n=55): Reduction markers of lung damage (desmosine) p<0.05)³
 - **Hospitalized COVID-19** (n=15): Faster 5-day clinical improvement in WHO severity scale⁴
 - Bronchiolitis Obliterans Syndrome (ongoing, n=13): Improvement biomarkers of lung damage and fibrosis, with signal of FEV1 stabilization)⁵

Phase 2 Bronchiectasis (Stockley et al 2013)

- 60 mg alvelestat or placebo BD for 4 weeks
- 38 randomized, 16 alvelestat, 22 placebo

Spirometry at week 4


Lung Function	Improvement over placebo LSM(SEM)	ver placebo P Value	
FEV ₁	100 mls (34.0)	0.006	
SVC	130 mls (74.0)	0.079	
SGRQ at week 4			
	Improvement over placebo LSM(SEM)*	P Value	
Total SGRQ	-5.64 (4.65)#	0.236	

*Negative value is improvement for SGRQ

#MCID of > 4 points reached, but high variability and statistical significance not reached



AATD – Progressive lung disease driven by Neutrophil Elastase



Alvelestat an Oral Neutrophil Elastase (NE) Inhibitor

- Targets the cause of lung damage
- Potential to treat early stages of lung disease to delay progression

Potential efficacy advantage


- Sustained NE suppression and effective lung penetration¹
- Inhibits NE on cell sites inaccessible to AAT²

Two complementary Phase 2 trials completed

- 162 patients with AATD-LD, 98 on alvelestat
- 12-week safety and efficacy investigated across range of respiratory impairments
- Data in augmentation naïve and on augmentation
- Phase 3 dose identified




Two Phase 2 studies in AATD-Lung Disease completed across different populations



No subjects on augmentation Patients with established disease Baseline scores (median): FEV₁ - 59% *SGRQ total score - 32.2 SGRQ activity - 53.3


Investigator-led study – Mark Dransfield, University of Alabama at Birmingham



~Half of subjects not on augmentation Patients earlier in their disease process Baseline scores (median): $FEV_1 - 89\%$ SGRQ total score - 19.6 SGRQ activity - 25.5



Alvelestat suppression of Blood Neutrophil Elastase Activity



- 120 mg reduction at week 12 ASTRAEUS p<0.05 (vs placebo)
- 240 mg reduction at week 12 ASTRAEUS <0.001 (vs placebo)
- 240 mg met target > 90% NE suppression in blood



Biomarkers and PK modelling confirm 240 mg dose for progression


ASTRAEUS

- 240 mg progressive reduction in biomarkers of NE-driven protein breakdown (Aα-val³⁶⁰) and elastin turnover (desmosine)
- 120 mg no effect on desmosine

ATALANTa

- Consistent with ASTRAEUS 120 mg had no effect on desmosine
- Significant reduction from baseline in $A\alpha$ -Val³⁶⁰ (p=0.03), but not significant compared to placebo

ASTRAEUS (Primary Endpoints)





Population PK modelling predicts 240 mg achieves target drug levels in lung tissue

Safety data from two AATD Phase 2 studies, builds on extensive safety database

	Alvelestat 240 mg N=40 (%)	Alvelestat 120 mg N=54 (%)	Placebo N=67 (%)
SAE	3 (7.5)	1 (1.9)	0 (0)
Adverse Events of Special Interest	11 (27.5)	10 (18.5)	18 (26.9)
Infections requiring antimicrobial therapy	10 (25.0)	10 (18.5)	18 (26.9)

Adverse Events of Special Interest

- Across both Phase 2 studies, no discrepancy was observed in number of infections vs placebo
- Single case (240 mg) of prolonged QTc in subject with history of prolonged QTc on concomitant therapy with known QTc effects
- Single case (240 mg) of elevated ALT>5xULN without raised bilirubin; asymptomatic and resolved. No Hy's Law cases.

Adverse events

• Headache was most frequent adverse event, generally mild or moderate and resolving on continued dosing. 3 cases reported as SAEs (240 mg)



Including legacy studies, safety database of 1,269 subjects exposed to alvelestat

Outcome of End-of-Phase 2 and Type C meetings

Phase 3 design End-of-Phase 2 meeting with FDA and scientific advice (EMA) to discuss endpoints for Phase 3 • registrational trial Subsequent Type C meeting held with the FDA and DCOA* Additional communications following Type C meeting SGRQ Total (FDA) and CT-density (EMA) independent primary endpoints For FDA "functional assessment" as key secondary • CT – EMA has indicated P<0.1 may be acceptable for approval Single study with enrollment of ~220 patients for up to 18 months – PI*ZZ patients with emphysema for full approval Initial gualitative validation study completed to support use of SGRO in AATD • Primary endpoints supported by ATALANTa and ASTRAEUS Phase 2 data for SGRQ including biomarker responders and significant correlation of desmosine with CT-density



Association of alvelestat treatment with improvement in Respiratory Health Status (SGRQ)

- St. George's Respiratory Questionnaire Patient reported outcome in COPD recognized by FDA
 - \circ Total score = Activity, Symptoms and Impacts domains
 - Activity domain most impacted in patients with AATD
- Potential tool for "feels and functions" endpoints required by the FDA for registrational trials in AATD
- In AATD studies, SGRQ Total score has been shown to deteriorate ~ 1 point per annum¹
- Phase 2 studies demonstrated a consistent association between the effects of alvelestat (biomarker reductions) and improvement in SGRQ (Total score and Activity Domain)^{2,3}
- Effect also observed for the COPD Assessment Test (CAT), another validated patient-reported quality of life tool
- ATALANTa study greater effect in SGRQ (Total score and Activity domain) in non-augmentation subgroup with earlier stage lung disease (FEV₁)




Earlier stage lung disease patients show greater SGRQ response

- ATALANTa study Non-augmentation subgroup (median FEV₁ 89.3%). Between group changes at week 12:
 - **SGRQ Total** = 4.7-point improvement (p=0.10)
 - **SGRQ Activity** = 10.0-point improvement (p=0.01)
- Post hoc analysis of ASTRAEUS and SGRQ Total change shows earlier stage patients also had the greatest improvement

Following FDA input, a qualitative validation study has been completed at several US sites to meet the initial requirements for SGRQ as a primary efficacy assessment in Phase 3. Study concluded:

> "The SGRQ is fit for purpose, content valid measure for patients with AATD-LD and is suitable for use as a key COA endpoint"

ATALANTa study (non-augmentation subgroup) – Change in SGRQ Total Score





32

Historical augmentation studies


Limited to FEV₁ <70% or <80% (Average FEV₁ in RAPID, EXACTLE ~50%)

- Patients earlier in their disease not eligible
- Intervening later may limit impact

Mereo's approach to Phase 3

No upper FEV₁ limit


- FEV_1 weighting towards patients >75%
- More patients eligible, including those not eligible for augmentation therapy
- Intervening earlier may have greater impact





PFT = Pulmonary function testing


Graphs adapted from Fraughen et al, Am J Resp Crit Care Med 2023 Nov 1;208(9):964-974. Reprinted with permission of the American Thoracic Society. Copyright © 2024 American Thoracic Society. All rights reserved. Showing FEV₁ decline over time in 615 AATD patients



Translating desmosine changes (elastin) to CT efficacy endpoint

		Augmentation therapy ¹	Alvelestat (240 mg, ASTRAEUS)
Desmosine (absolute reduction	Month 3	-0.013 ng/ml	-0.028 ng/ml†
from baseline, mean)	Month 12	-0.031 ng/ml	Study duration 12 weeks

Effects progressive over 12 weeks and from augmentation experience expected to continue over the course of 2-4 years¹





Development strategy for Phase 3 registrational trial

Clinical data	Earlier stage severe PI*ZZ patients observed to have greater response in SGRQ Total and Activity scores Literature indicates that earlier stage patients with higher FEV ₁ may be more likely to show spirometry benefit		
Execution of the Phase 3	Study population of AATD patients with a broad range of stage of disease (early → late stage) may accelerate enrollment Studies confirm 240 mg dose selection		Broader population maximizes potential for clinical and commercial success
Commercial opportunity	Opportunity for broad label including earlier stage PI*ZZ patients who may not be eligible for AAT augmentation – payors and HCPs familiar with SGRQ Total and CT endpoints Partnering process ongoing – range of structures		

.





Other programs, milestones and financials



Key milestones for core programs





Other programs

Other current partnerships

Navicixizumab – global rights out-licensed to Feng Biosciences for further development in ovarian cancer

• Payments of up to \$300 million in milestones plus royalties

Leflutrozole – global rights out-licensed to ReproNovo for further development

- ReproNovo is a reproductive medicine company
- Upfront plus up to \$64 million in milestones and royalties

Partnering opportunities

Etigilimab – anti-TIGIT which has completed a Phase 1b basket study in a range of rare tumor types in combination with nivolumab. It is currently in a Phase 1b/2 investigator led study at the MD Anderson in clear cell ovarian cancer in combination with nivolumab, which has been expanded from the initial 10 patients to 20 patients. This study is funded by the Focus Fund.

Acumapimod – a P38 MAP kinase inhibitor which has successfully completed a Phase 2 study in Acute Exacerbations of chronic obstructive pulmonary disease (AECOPD) in 282 patients



Financial highlights

Cash runway into 2027 \$87.5 million as of June 30, 2024

Cap Table (June 2024)	ADSs (in thousands)
Shareholders > 2% holding Shareholders < 2% holding	79,675 74,089
Share capital – Issued and outstanding as of June 30, 2024 ¹	153,764
Potential Future Dilution:	
Warrants ²	1,401
Convertible loan notes	3,421
Employee share schemes ³	12,349

¹ ADS equivalents of 768,821,274 ordinary shares, with one ADS representing five ordinary shares. ² Assumes a market price of \$4.00 per ADS and cashless exercise. The maximum number of warrants outstanding is 1.8m.

³ Excludes 1.4m ADSs for employee share awards with an exercise price in excess \$8.00; Most employee share awards have an exercise price between ~\$1.00 - \$6.00.



Thank you

With a special thank you to members of our community, who generously agreed to be featured in this presentation.



APPENDIX






Setrusumab (BPS-804)

Mouse models and HR-pQCT




Brittle mouse model (Brtl/+)- treatment with BPS-804 (setrusumab)


Mature Btrl control




Mature Brtl treated



Mature WT Control



Mature WT Treated






Brtl – brittle mouse model

WT – wild type

HR-pQCT scans of patients with **OI** and controls





The OFLEY STUDY and HR-pQCT

- Prospective study investigating the prediction of fracture (Fx) by bone microarchitecture assessed by HR-pQCT in postmenopausal women
- HR-pQCT used to measure microarchitecture at the distal radius and tibia in 589 women (mean 68 years old)
- During 9 year follow up 135 women sustained a fracture including 81 women with a major osteoporotic fracture
- After adjusting for age, women who had fractures had significantly lower total and trabecular volumetric densities (vBMD) at both sites as determined by HR-pQCT
- OI patients have fewer and thinner trabeculae and increased cortical porosity






Etigilimab (MPH313)

Anti-TIGIT antibody in development in combination with anti-PD1



Etigilimab: an Anti-TIGIT antibody in development in combination with anti-PD1

- T Cell Immunoreceptor with IG and ITIM domains (TIGIT)
- Anti-TIGIT designed to activate the immune system and enable anti-tumor activity
- Expressed on CD4, CD8 and NK cells and expression is pronounced on regulatory T cells (Tregs)
- TIGIT mediates an inhibitory signal that is thought to prevent T-cells from attacking tumor cells
- Etigilimab is an IgG1 monoclonal antibody designed to balance affinity and ADCC characteristics while limiting side effects
- Completed Phase 1a (etigilimab monotherapy)/1b (combined with nivolumab)
- Phase 1b open label basket study in combination with nivolumab (ACTIVATE) enrollment in selected cohorts; data presented at ASCO 2022 and ESMO 2022 and 2023
- Combination of etigilimab and nivolumab was safe and well tolerated





ACTIVATE efficacy data: select cohorts*



Objective Responses by RECIST	Cohort						
	Endometrial Cancer (CPI-naïve) (n=10)	Cervical Cancer (n=8)^	Uveal Melanoma (n=8)	De-differentiated Liposarcoma (n=10)	Germ Cell Tumor (n=4)	Total (n=40)	
ORR = 10 (25%)	1	1 (0)	((0,	(·· · ·)		
CR	0	31	0	0	0	3	
PR	3	0	2	1	13	7	
SD	3	2 ²	2	4	0	11	
PD	4	3	4	5	3	19	

Disease Control Rate (CR+PR+SD) = 21 of 40 (52.5%)

All responses confirmed

*Efficacy analysis set: Best Observed Response (BOR) by investigator-assessed response per RECIST 1.1/clinical progression; data cut-off 3/29/2023. ^ Includes 1 TMB-H cervical pt E025 with CPS >1% by central lab.

Mereo BioPharma


1. 1 CR was on-going and pt withdrew consent; 1 CR off study due to AE; 1 CR on-going at data cut-off

2. 1 SD on-going at data cut-off, patient died due to unrelated event

3. Mixed response, continued treatment, PD-RECIST1.1

Central lab PD-L1 CPS % for ORR pts: F088 germ cell=0; F047 sarcoma=1; F030 uveal=0; A075 endometrial=3; A103 endometrial=3; G101 endometrial=3; C081 cervical=51; C040=20; C001 cervical and F110 uveal had no tissue for central lab; pathology report for C001 indicated >90%.

ACTIVATE efficacy data: select cohorts (continued)



Waterfall Plot - Percent Change/Subject Number Efficacy Analysis Set*

^Cervical cancer patient (E025) enrolled in IMB-H cohort with PD-L1 CPS>1%


- ^^ Endometrial cancer CPI-naïve patient (G101) enrolled in post-CPI cohort
- ^^ Sarcoma subjects only include those with de-differentiated liposarcoma



+ best overall response of stable diseases. Note 2 subjects with SD had progression (non-target lesion) concurrent with the first scan F049=sarcoma; H045=ovarian; F018 & F020=uveal

#De-differentiated liposarcoma subject F047 is CR for target lesions, but overall PR due to persistent non-target lesion

ACTIVATE efficacy data: select cohorts (continued)



" Sarcoma subjects only include those with De-differentiated liposarcoma ^Cervical cancer patient (E025) enrolled in TMB-H cohort with PDL-1 CPS>1% ^^Endometrial cancer - CPI naïve patient (G101) enrolled in post-CPI cohort Note E025 death unrelated to study drug or PD. C001 consent withdrew Central lab PD-L1 CPS status pts on study \geq 335 days: * PD-L1 negative; + PD-L1 \leq 3; #PD-L1 >3



Data cut-off March 29, 2023; 7 pts on-going (\rightarrow)


PR(7 pts) = 11 months

SD(11 pts) = 5.7 months

•

٠

EON* investigator-led study at MD Anderson Phase 1b/2 in Clear Cell Ovarian Carcinoma



Two Stage Phase 1/2 design with stopping boundaries for efficacy and toxicity. Based on responses from initial 10 patients, study is being expanded to 20 patients.



Mereo BioPharma Group plc

4th Floor, One Cavendish Place London W1G 0QF United Kingdom +44(0)333 023 7300

